Sorry, you need to enable JavaScript to visit this website.

Screening Programs Steering Group

The objective of the Screening Programs Steering Group is to extend healthy life years, improve quality of life, and reduce health inequalities through effective screening programs. To achieve this, the group monitors the quality of population-based screenings, coordinates organizational tasks across various institutions, and ensures the overall effectiveness of the screening programs.

The tasks of the Steering Group include:

  • Evaluating the effectiveness of all ongoing screening programs;
  • Approving proposals for methodological changes and adjustments to target groups in ongoing screenings;
  • Providing guidelines for initiating new national screening programs and activities that support the development of a sustainable screening program. If necessary, the Steering Group has the authority to commission feasibility analyses, pilot studies, or health technology assessments for these new programs;
  • Formulating Estonia’s sectoral positions for international organizations as needed.

Members of the Steering Group base their work on principles of evidence-based practice and good governance, avoiding conflicts of interest, and grounding their decisions in:

  • The objectives set out in the Public Health Development Plan and the Estonian Cancer Control Plan,
  • Conclusions from health technology assessments,
  • The results of feasibility and pilot studies, and
  • The readiness of the healthcare community.

The criteria set by the World Health Organization for initiating population-based screening programs include:

  • The condition being a significant public health concern;
  • The presence of a detectable preclinical or early symptomatic phase of the disease;
  • A clear understanding of the natural history of the disease, including its progression from latent to symptomatic stages;
  • The screening tests should be acceptable to the target population;
  • An effective treatment should be available for patients diagnosed through screening;
  • The benefits of screening must outweigh any potential physical or psychological harms;
  • The effectiveness of the screening program must be supported by high-quality scientific evidence;
  • The costs of detecting the disease (including diagnosis and treatment of diagnosed patients) should be justified relative to overall healthcare expenditure;
  • The healthcare system must have the capacity to manage the additional clinical workload generated by screening;
  • The screening program must be sustainable and integrated into the existing healthcare system, rather than being a temporary or short-term initiative.

Last updated: 14.07.2025

search block image